Superworth

Neogenomics NEO

Specialty Business Services, Industrials
$16.49
−5.12%
Market cap
$2.1B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.7×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$787.8M
+11% on a year ago
Net margin
−4.1%
Free cash flow yield
−1.3%

Neogenomics trades at 2.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $787.8M over the last twelve months, up 11% on a year earlier with a −4% net margin.

Charts

Financials

Income statement for NEO, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$155.6M+12%$156.2M+14%$164.5M+12%$167.8M+10%$172M+11%$168M+8%$181.3M+10%$187.8M+12%$190.2M+11%$186.7M+11%$201.7M+11%$209.3M+11%
Cost of revenue$88M+7%$90.8M+10%$92M+6%$92.9M+4%$94.7M+8%$94.8M+4%$104.1M+13%$107.4M+16%$106.8M+13%$105.8M+12%$109.8M+6%$112.7M+5%
Gross profit$67.6M+19%$65.5M+19%$72.5M+21%$74.9M+20%$77.3M+14%$73.2M+12%$77.3M+7%$80.4M+7%$83.3M+8%$80.9M+10%$91.9M+19%$96.6M+20%
R&D$7.1M+7%$7.6M+3%$7.9M+5%$7.7M+45%$8M+12%$10.2M+34%$9M+14%$8.7M+13%$9.2M+15%$9.5M−6%$10.8M+19%$9.9M+13%
SG&A$77.8M+8%$86M+11%$85M+7%$87.4M+11%$86M+11%$90.9M+6%$95.8M+13%$91.7M+5%$87M+1%$89.6M−2%$90.9M−5%$94.7M+3%
−$18.6M−30%−$30.6M−13%−$21.9M−27%−$21.2M−12%−$18.4M−1%−$27.8M−9%−$47.6M+117%−$27M+27%−$13.4M−27%−$18.2M−34%−$9.8M−80%−$7.9M−71%
Interest expense$1.7M$1.7M−4%$1.7M−7%$1.6M−3%$1.6M−3%$1.6M−4%$933K−44%$603K−63%$599K−63%$598K−63%$781K−16%$1.3M+110%
Pre-tax income−$15.3M−40%−$27.7M−18%−$19M−29%−$17.8M−17%−$16.1M+6%−$25.7M−7%−$45.8M+141%−$26.4M+48%−$12.4M−23%−$17.6M−32%$1.8M−$8M−70%
−$960K−66%−$620K−79%−$375K−84%−$150K−95%−$804K−16%$266K−$724K+93%$740K−$2.5M+214%−$472K−$412K−43%−$475K
Net income−$14.3M−37%−$27.1M−12%−$18.6M−23%−$17.7M−4%−$15.3M+7%−$25.9M−4%−$45.1M+142%−$27.1M+53%−$9.9M−36%−$17.1M−34%$2.2M−$7.5M−72%
−$0.11−39%−$0.21−16%−$0.15−21%−$0.14−7%−$0.12+9%−$0.20−5%−$0.35+133%−$0.21+50%−$0.08−33%−$0.13−35%$0.02−$0.06−71%
125.9M+1%126.1M+1%126.4M+1%127M+1%127.2M+1%127.4M+1%127.9M+1%128.4M+1%128.6M+1%129.2M+1%130.8M+2%128.6M+0%

EPS, diluted: 10 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY14: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Specialty Business Services nearest Neogenomics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
NEONeogenomics$2.1Bn/m139×2.7×+11%−4.1%
MHMcGraw Hill$2.4B25.6×27.4×1.2×+0%4.4%
VVXV2X$2.6B28.7×15.0×0.5×+13%1.9%
DFINDonnelley Financial Solutions$1.6B17.9×18.7×2.1×+5%12.4%
CRAICRA International$1.2B26.3×21.9×1.6×+11%6.2%
ITGartner$14.9B21.1×41.4×2.3×+1%12.0%
ULSUL Solutions$15.2B30.3×42.8×4.8×+7%16.1%
Peer median$2.5B25.9×24.6×1.8×+6%9.1%

More on Neogenomics

Each number over time

Where it ranks

Its groups

About

Industry
Specialty Business Services
Sector
Industrials

Valuation data, not investment advice. Prices as of .